Economics of coronary stenting and GPIIb/IIIa blockade.
Weintraub
W S
WS
D000077284:Abciximab; D000800:Angioplasty, Balloon / Q000191:economics*; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000191:economics* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D015607:Stents / Q000191:economics*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab